Celadon Pharmaceuticals PLC - London-based pharmaceutical company focusing on cannabis-based medicines - Confirms Jonathan Turner will formally join the company on Tuesday as chief financial officer, further to an announcement on November 1. He succeeds Katie Long. Turner joins from Oxford Instruments PLC, where he served as director of accounting, tax and treasury. He began a phased transition to the role from November, when Celadon said it expected Turner to join on a full-time basis and be appointed to the board from February. This was brought forward.

Current stock price: 51.50 pence

12-month change: down 60%

Copyright 2023 Alliance News Ltd. All Rights Reserved.